These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30179703)

  • 1. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled dry powder formulations for treating tuberculosis.
    Das S; Tucker I; Stewart P
    Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder inhalable formulations for anti-tubercular therapy.
    Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis.
    Aekwattanaphol N; Das SC; Khadka P; Nakpheng T; Ali Khumaini Mudhar Bintang M; Srichana T
    Int J Pharm; 2024 Oct; 664():124608. PubMed ID: 39163929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
    Mehta P; Bothiraja C; Kadam S; Pawar A
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhalers of antitubercular drugs.
    Nainwal N; Sharma Y; Jakhmola V
    Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
    Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
    AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary drug delivery systems for tuberculosis treatment.
    Pham DD; Fattal E; Tsapis N
    Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
    Patil TS; Deshpande AS; Deshpande S; Shende P
    J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
    Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
    Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
    Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
    Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry powder inhalation: past, present and future.
    de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
    Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
    Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
    Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technological and practical challenges of dry powder inhalers and formulations.
    Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
    Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.